Mandate

Vinge ADVISES Tele2 IN CONNECTION WITH SALE OF CABLE AND FIBRE OPERATIONS

October 23, 2013

Vinge is advising Tele2 in connection with the sale of its cable and fibre operations on the private market and the private customers pertaining thereto to Telenor. The total cash consideration amounts to SEK 794 million of which approximately SEK 250 constitutes capital gains. The transaction relates to approximately 125 000 fixed broadband customers and approximately 75 000 digital TV customers. Telenor’s acquisition is subject to the approval of the Swedish Competition Authority.

Partner Johan Winnerblad together with, among others, associates Nina Farrahi, Mikael Satama Granberg and Jonatan Lund Kirkhoff are advising Tele2. Partner Johan Karlsson and associate Grant McKelvey are providing competition law advice and associate Åsa Gotthardsson is providing employment law advice.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024